Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Fineline Cube Dec 30, 2025
Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Fineline Cube Dec 30, 2025
Company Drug

Pfizer’s Elrexfio Anticipated for Priority Review in China for Relapsed/Refractory Multiple Myeloma

Fineline Cube Mar 19, 2024

The Center for Drug Evaluation (CDE) in China has indicated that Pfizer (NYSE: PFE)’s Elrexfio...

Policy / Regulatory

CDE Seeks Public Feedback on Latest Batch of Generic Drug Reference Preparations

Fineline Cube Mar 19, 2024

The Center for Drug Evaluation (CDE), a key regulatory body overseeing pharmaceutical evaluations in China,...

Company Drug

AstraZeneca Caps Monthly Costs for US Patients with Asthma and COPD Inhalers

Fineline Cube Mar 19, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced an expansion of its...

Company Drug

Jiangsu Yahong Meditech to Present Phase III Results for Cervical Cancer Treatment at SGO Annual Meeting

Fineline Cube Mar 19, 2024

Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, is...

Company Medical Device

Sino Medical Sciences Secures South Korean Approvals for Three Cardiovascular Devices

Fineline Cube Mar 19, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...

Company Deals

Bio-Thera Solutions and SteinCares Ink Licensing Deal for LatAm Biosimilar Distribution

Fineline Cube Mar 19, 2024

Bio-Thera Solutions (SHA: 688177), a Chinese biopharmaceutical company, has entered into a licensing agreement with...

Company Deals

C&Y Pharmaceutical Teams Up with GigaCeuticals to Form AI-Driven Drug Development JV

Fineline Cube Mar 19, 2024

Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254), a Chinese pharmaceutical company, is venturing into...

Company Drug

GSK’s Jemperli Shows Survival Benefits in Phase III Endometrial Cancer Study

Fineline Cube Mar 19, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has presented early results from a...

Company

Akeso Biopharma Reports Record Revenue and First Profit, Driven by Innovative Drugs

Fineline Cube Mar 19, 2024

Akeso Biopharma (HKG: 9926) has announced its financial results for 2023, reporting a record revenue...

Company Deals

uBriGene Partners with XJTLU to Develop CAR-NK Cell Therapies for Solid Tumors

Fineline Cube Mar 18, 2024

uBriGene, a China-based biotechnology company, has entered into a partnership with Xi’an Jiaotong-Liverpool University (XJTLU)...

Company Deals Drug

Boehringer Ingelheim Partners with Sosei Group to Develop GPR52 Agonists for Schizophrenia

Fineline Cube Mar 18, 2024

Boehringer Ingelheim (BI), headquartered in Germany, has entered into a global collaboration and exclusive option-to-license...

Company Drug

BeiGene’s Tislelizumab Receives FDA Approval for Esophageal Squamous Cell Carcinoma

Fineline Cube Mar 18, 2024

BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration (FDA) has granted...

Company Deals

Hansoh Pharmaceutical Secures Global Rights to Biotheus’ BsAb HS-20117/PM1080

Fineline Cube Mar 18, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has...

Company Policy / Regulatory

Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use

Fineline Cube Mar 18, 2024

GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...

Company Drug

Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use

Fineline Cube Mar 18, 2024

GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...

Company Deals

Microenergy Medical Technology Secures Pre-Series A Funding to Advance Medical Devices

Fineline Cube Mar 18, 2024

Microenergy Medical Technology Co., Ltd, a Hangzhou-based manufacturer of active intervention medical devices, has reportedly...

Company Deals

Getein Biotech Partners with Dymind Biotechnology to Advance IVD Market Presence

Fineline Cube Mar 18, 2024

Getein Biotech Inc., (SHA: 603387), a company based in China with a focus on in...

Company Deals

CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development

Fineline Cube Mar 18, 2024

CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into...

Company Drug

Simcere Pharmaceutical’s Suvemcitug Files for Approval in China for Recurrent Ovarian Cancer

Fineline Cube Mar 18, 2024

Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that an...

Company Drug

Bristol Myers Squibb’s Breyanzi Receives FDA Accelerated Approval for CLL/SLL Treatment

Fineline Cube Mar 18, 2024

The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s...

Posts pagination

1 … 325 326 327 … 603

Recent updates

  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
  • Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline
  • Broncus Medical Acquires Valgen Stake from Venus for $15 Million
  • CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug
  • Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.